Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGC · Real-Time Price · USD
4.920
-0.010 (-0.20%)
Dec 20, 2024, 4:00 PM EST - Market closed
RGC Employees
Regencell Bioscience Holdings had 12 employees as of June 30, 2024. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$358,486
Market Cap
64.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 12 | 0 | - |
| Jun 30, 2023 | 12 | -1 | -7.69% |
| Jun 30, 2022 | 13 | -1 | -7.14% |
| Jun 30, 2021 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| 111, Inc. | 1,520 |
| Agenus | 389 |
| Prenetics Global | 324 |
| InterCure | 270 |
| Rockwell Medical | 237 |
| OptiNose | 132 |
| Hyperfine | 131 |
| Cue Biopharma | 53 |
RGC News
- 2 years ago - Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial - Business Wire
- 2 years ago - Slow And Steady Wins The Race With Regencell Bioscience - Seeking Alpha
- 2 years ago - Sector Rotation And 9 Stocks To Watch During A Recession - Benzinga
- 2 years ago - Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period - Business Wire
- 2 years ago - Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO - Business Wire
- 3 years ago - Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network - Accesswire
- 3 years ago - Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms - Benzinga
- 3 years ago - Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial - Business Wire